---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-361760"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2021-12-20T23:59:59+00:00"
generated_at: "2026-06-27T23:44:07.547747+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CRISPR Therapeutics terminates EVP R&D Tony W. Ho without cause

## Summary
- Tony W. Ho terminated as Executive Vice President, Research and Development on December 14, 2021.
- Termination is without cause and not the result of any disagreement with the Company.
- No replacement has been announced; Samarth Kulkarni remains CEO.

## SEC filing metadata
- accession: 0001193125-21-361760
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2021-12-20T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000119312521361760/0001193125-21-361760-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000119312521361760/d274235d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-361760
- JSON: https://secwatch.observer/filing/0001193125-21-361760.json
- Plain text: https://secwatch.observer/filing/0001193125-21-361760.txt

## Key facts
- Executive change
  Tony W. Ho was terminated as Executive Vice President, Research and Development at CRISPR Therapeutics AG.
  - Action: terminated
  - Role: Executive Vice President, Research and Development
  source text: On December 14, 2021, Tony W. Ho was terminated from his position as Executive Vice President, Research and Development of CRISPR Therapeutics AG (the “Company”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1674416/000119312521361760/0001193125-21-361760-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.